Mechanisms of Vancomycin Resistance in Staphylococcus aureus

Staphylococcus aureus has historically remained susceptible to vancomycin, a glycopeptide antibiotic targeting cell wall synthesis. Resistance has emerged through multiple, often overlapping, mechanisms. High‐level resistance arises via acquisition of the vanA operon, typically transferred from enterococcal species, which reprogrammes peptidoglycan precursors to terminate in D‐alanine‐D‐lactate, markedly reducing vancomycin binding. Intermediate resistance (VISA) is mediated by mutations in two‐component regulatory systems such as VraSR, WalKR and GraSR, leading to cell wall thickening, reduced autolysis and altered cross‐linking. These changes increase the pool of uncross‐linked peptidoglycan stems that sequester vancomycin before it reaches its true targets. Additional mutations in genes encoding d‐alanine‐d‐alanine ligase, RNA polymerase subunits and central metabolic enzymes further fine‐tune resistance and may offset the fitness cost imposed by altered cell wall architecture. Heterogeneous resistance phenotypes arise when small subpopulations within a clonal culture exhibit elevated resistance, complicating detection and clinical management. The global rise of VISA, heterogeneous VISA (hVISA) and vancomycin‐resistant S. aureus (VRSA) underscores the need for robust surveillance and stewardship. Understanding these mechanisms informs the development of next‐generation inhibitors and diagnostics to preserve vancomycin efficacy.

Research from Nature Portfolio

Recent meta‐analytical work has quantified the global prevalence and distribution of VRSA, VISA and hVISA among clinical isolates. Data spanning two decades show a two‐ to fourfold increase in all categories since 2010, with notable geographic hotspots in Asia and North America. Subgroup analyses reveal that hVISA is more frequently isolated from bloodstream infections, while VISA predominates in respiratory and skin‐soft‐tissue samples. These findings highlight regional variability in resistance trends and emphasise the necessity of standardised definitions and susceptibility testing protocols to ensure comparability across surveillance networks.

Mechanisms of Vancomycin Resistance in Staphylococcus aureus publication trend

The graph below shows the total number of articles in mechanisms of vancomycin resistance in staphylococcus aureus across all publications each year (not limited to Nature Index journals).

Technical terms

VanA operon: Gene cluster encoding enzymes that replace the D‐alanine‐D‐alanine terminus of peptidoglycan precursors with D‐alanine‐D‐lactate, conferring high‐level vancomycin resistance.

VISA (Vancomycin‐intermediate Staphylococcus aureus): Strains with moderately elevated vancomycin minimum inhibitory concentration (4–8 μg/mL) linked to cell wall thickening and regulatory mutations.

VRSA (Vancomycin‐resistant Staphylococcus aureus): Strains harbouring the vanA operon displaying high‐level resistance (MIC ≥16 μg/mL).

Two‐component regulatory system (TCS): Paired sensor kinase and response regulator proteins that detect environmental cues and modulate gene expression, central to cell wall stress responses.

Heteroresistance: Phenomenon in which a minor subpopulation within a bacterial culture exhibits significantly higher antibiotic resistance than the bulk population, often evading standard susceptibility tests.

References

1. Genetic Pathway in Acquisition and Loss of Vancomycin Resistance in a Methicillin Resistant Staphylococcus aureus (MRSA) Strain of Clonal Type USA300. PLOS Pathogens (2012).
2. Molecular Events for Promotion of Vancomycin Resistance in Vancomycin Intermediate Staphylococcus aureus. Frontiers in Microbiology (2016).
3. Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis. Scientific Reports (2020).
4. Vancomycin-resistant Staphylococcus aureus (VRSA) can overcome the cost of antibiotic resistance and may threaten vancomycin’s clinical durability. PLOS Pathogens (2024).